Cowen & Co. analyst Ken Cacciatore maintained a Buy rating on Dermira (DERM) on November 7 and set a price target of $25. The company’s shares closed on Friday at $10.56, close to its 52-week low of $6.98.
According to TipRanks.com, Cacciatore is a 3-star analyst with an average return of 1.8% and a 45.8% success rate. Cacciatore covers the Healthcare sector, focusing on stocks such as Liquidia Technologies Inc, Alder Biopharmaceuticals, and Adamas Pharmaceuticals.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Dermira with a $18.33 average price target, representing a 73.6% upside. In a report issued on October 23, Cantor Fitzgerald also maintained a Buy rating on the stock with a $20 price target.
.
See today’s analyst top recommended stocks >>
Based on Dermira’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $66.54 million. In comparison, last year the company had a GAAP net loss of $179 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Dermira, Inc. is a biopharmaceutical company, which engages in the provision of biotech ingenuity to medical dermatology. It focuses on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis, psoriasis, and acne.
